Followers | 283 |
Posts | 1162 |
Boards Moderated | 0 |
Alias Born | 10/04/2020 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, November 27, 2020 10:54:56 PM
IMO
1. All filings current
2). Merger finalized (valuation increases significantly here)
PPS= 0.10-0.35
3). Initial funding in place
4). Studies underway at Texas A&M
5). Expansion of Clone-3 testing to neutralize Covid-19 for Fast Track by FDA via Phase III Trial that will likely be conducted in tandem with a HIV Phase III Trial (keep in mind that Protheragen has already taken Clone-3 through the "Pre-Clinical" Phase and may have possibly completed both Phase I & 2 by now although their website doesn't show this)
6). Primate Studies initiated at U.C. Davis
PPS= 0.50-1.50
7). Transition to Phase IV clinical trials (both HIV & Covid-19)
8). Additional funding (multiple sources)
PPS = 1.55-2.00
9). Big Pharma Partner name for global commercialization
PPS= 2.50-5.00
Again, this is ONLY an Opinion nothing else!
I invite any and all feedback on the time line of these events, and/or others, with corresponding estimated PPS. Also, if I missed something, please let me know.
Be well and prosper...
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM